One of several pharmaceutical companies in the Danbury area, Mannkind got a big boost this past year when the company received U.S. Food and Drug Administration approval for its Afrezza, an inhalable form of insulin under development by the company as its main product candidate. Matt Pfeffer, the chief financial officer for the company, said recently that the company initially expects to produce up to 400 million units of the drug, the only inhalable insulin on the market today with FDA approval.
via Danbury Newswire http://ift.tt/1Bqxnx9
via Danbury Newswire http://ift.tt/1Bqxnx9
No comments:
Post a Comment